Big Sky Biomedical has appointed Ryan Egeland as managing director.
“Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine,” said Egeland. “I am extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I look forward to addressing significant underserved patient populations and large unmet clinical needs through compelling and differentiated technologies.”
Egeland received his medical degree from Harvard Medical School (Boston, USA) and was a Rhodes Scholar at the University of Oxford (Oxford, UK) where he completed his PhD and MBA. Previously, he served as the head of strategic ventures and Chief Medical Officer for Cardiovascular Systems (CSI).
Prior to his tenure at CSI, Ryan led teams in business development and licensing, medical and scientific affairs, and product marketing at Medtronic, Covidien, and ev3. Before this, he trained as a plastic and reconstructive surgeon at Northwestern Memorial Hospital (Chicago, USA) and has practiced in both large academic hospital and office-based lab settings.
“We are exceedingly pleased to welcome Ryan in a managing role at Big Sky Biomedical,” stated JC Sun, founding partner of the company. “Ryan brings extensive, cross-functional expertise to our nimble, capital-efficient companies. With his guidance and operational involvement, not only am I very confident in our ability to execute in the near term, but am extremely bullish about Big Sky’s potential to streamline zero to one value creation, setting a new standard for accelerating next-level medical device design and development.”